

**NORRIS MEDICINES LIMITED**

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrispharma.com. Website: www.norrispharma.com

CIN No. L24230MH1990PLC058071.

PART -1		Rs. In Lakhs					
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2015							
Sl. No.	Particulars	QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2015	30.06.2015	30.09.2014	30.09.2015	30.09.2014	31.03.2015
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	(a) Net Sales/Income from Operations	558.68	367.14	523.20	925.82	890.34	1867.79
	(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00	12.88
	Total Income From Operations ( Net)	558.68	367.14	523.20	925.82	890.34	1880.67
2	Expenses						
	a. Cost of Materials Consumed	272.55	202.79	281.16	475.34	483.95	913.34
	b. Purchase of Stock in Trade	0.00	0.00	0.00	0.00	0.00	0.00
	c. Changes in Inventories of Finished Goods, work in Progress and stock in trade	5.90	-48.83	2.11	-42.93	-46.72	-1.33
	d. Employee Benefit Expenses	127.10	100.56	102.09	227.66	202.65	408.36
	e. Depreciation and Amortisation Expense	31.47	31.47	31.22	62.94	62.69	131.23
	f. Loss/Gain on Foreign Exchange Transactions	-0.05	-0.45	0.00	-0.50	-0.45	-0.34
	g. Other expenditure	93.62	91.06	103.73	184.68	194.79	376.94
	Total Expenses	530.59	376.60	520.31	907.19	896.91	1828.20
3	Profit from operations before Other Income and Finance Cost (1-2)	28.09	-9.46	2.89	18.63	-6.57	52.47
4	Other Income	1.94	4.11	0.14	6.05	4.25	2.03
5	Profit before Finance Costs (3+4)	30.03	-5.35	3.03	24.68	-2.32	54.50
6	Finance Costs	15.83	13.16	13.15	28.99	26.31	53.81
7	Profit/ Loss before Tax (5-6)	14.20	-18.51	-10.12	-4.31	-28.63	0.69
8	Tax Expense	0.00	0.00	0.00	0.00	0.00	105.04
9	Net profit (+)/Loss (-) for the period (7-8)	14.20	-18.51	-10.12	-4.31	-28.63	-104.35
10	Paid-up equity share capital ( Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
11	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year						-463.48
12	Earnings Per Share (EPS) - Face Value of Share Rs. 10/ each ( Not Annualised)						
	- Basic and diluted	0.14	-0.19	-0.10	-0.04	-0.29	-1.04

**NORRIS MEDICINES LIMITED**

Regd Off: 801/P, GIDC Estate, Ankleshwar, 393002, Gujarat.

Phone: 02646-223462 Fax 02646 -250126.

email: contact@norrisspharma.com. Website: www.norrisspharma.com

CIN No. L24230MH1990PLC058071.

**PART -II**

**Select Information for the Quarter Ended 30.09.2015**

Sl. No.	Particulars	Quarter Ended 30.09.2015	Quarter Ended 30.06.2015	Quarter Ended 30.09.2014	Six Months ended 30.09.2015	Six Months ended 30.09.2014	Previous accounting year ended 31.03.2015
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>						
1	Public Shareholding						
	-No. of shares	6596069	6596069	6596069	6596069	6596069	6596069
	-Percentage of shareholding	65.96	65.96	65.96	65.96	65.96	65.96
	Promoters and promoter group						
2	Shareholding						
a)	Pledged/Encumbered						
	-No. of shares	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
	- Percentage of shares (as a% of the total share capital of the Company)	Nil	Nil	Nil	Nil	Nil	Nil
b)	Non-encumbered						
	-No. of shares	3404631	3404631	3404631	3404631	3404631	3404631
	- Percentage of shares (as a % of the total shareholding of Promoter and Promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of shares (as a% of the total share capital of the Company)	34.04	34.04	34.04	34.04	34.04	34.04

PARTICULARS	Quarter Ended 30.09.2015
<b>B. INVESTORS COMPLAINTS</b>	
Pending at the beginning of the Quarter	
Received during the quarter	Nil
Disposed off during the quarter	03
Remaining unresolved at the end of the quarter	03
	Nil

**Notes:**

- 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 14.11.2015. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 3) There are no exceptional/ extraordinary items during the quarter ended 30.9.2015.
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures


Date: 14.11.2015  
Place: Ankleshwar

For Norris Medicines Limited

  
Vimal D Shah  
Managing Director

STATEMENT OF ASSETS AND LIABILITIES		
	30.09.2015	31.03.2015
	Un audited	(Audited)
<b>1. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	992.57	992.57
(b) Reserves & Surplus	-467.77	-463.48
<b>(2) Share Application money pending allotment</b>		
<b>(2) Non - Current Liabilities</b>		
(a) Long Term borrowings	748.93	748.93
(b) Long Term provisions		
<b>(3) Current Liabilities</b>		
(a) Short Term borrowings	17.04	67.32
(b) Trade payables	312.46	279.16
© Other current liabilities	101.15	98.01
(d) Short Term provisions	99.91	92.84
<b>TOTAL</b>	<b>1804.29</b>	<b>1815.35</b>
<b>II. ASSETS</b>		
<b>(1) Non -current assets</b>		
<b>(a) Fixed Assets</b>		
(i) Tangible assets	807.33	861.06
(ii) Capital Work in Progress		
(b) Non Current investments	0.86	0.86
© Deferred tax assets (net)	122.03	122.03
(d) Long Term Loans and Advances	67.84	132.40
<b>(2) Current Assets</b>		
<b>(a) Current investments</b>		
(b) Inventories	375.44	250.03
© Trade Receivables	323.53	376.51
(d) Cash & cash equivalents	31.86	20.00
(e) Short Term Loans and advances	75.40	52.46
(f) Other Current assets		
	<b>1804.29</b>	<b>1815.35</b>

For Norris Medicines Limited



Vimal D Shah  
Managing Director

Date: 14.11.2015  
Place: Ankleshwar

**LIMITED REVIEW REPORT**

We have reviewed the accompanying statement of unaudited financial results of Norris Medicines Limited At Ankleshwar registered Office 901/3, 4, 5, 801/P & 802, GIDC Industrial Estate, Ankleshwar-393 002 (Gujarat) for the quarter ended 30.09.2015 except For the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.


We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards notified to the Companies (Accounting Standard) Rules, 2006, the relevant provisions of the Companies Act, 1956 read with general circular 15/2013 dated 13<sup>th</sup> September, 2013, issued by Ministry of Corporate Affairs in respect of section 133 of the Companies Act, 2013 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : BHARUCH  
Date : 14<sup>th</sup> November, 2015

232, Rangoli Complex,  
Station Road,  
Bharuch – 392 001  
Gujarat.

For, MINU MODI & CO.  
Chartered Accountants

  
CA MINU MODI  
Proprietor  
M. No. 100289  
(Firm Reg. No. 119948W)

